X4 Pharmaceuticals, Inc
XFOR$15M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaBOSTON143 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
XFOR News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
Mavorixafor
WHIM Syndrome
X4P-001
WHIM Syndrome
axitinib
Clear Cell Renal Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mavorixafor | Phase 3 | WHIM Syndrome | - | - |
X4P-001 | Phase 2 | WHIM Syndrome | - | - |
axitinib | Phase 2 | Clear Cell Renal Cell Carcinoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply